The EPOS 2020 criteria for initiating biologic treatment in patients with CRSwNP—including type 2 inflammation (tissue eosinophils ≥ 10 cells/HPF, blood eosinophils ≥ 250 cells/μL, or total IgE ≥ 100 IU/mL), corticosteroid requirements (≥ 2 courses/year or long-term low-dose use) or contraindication to them, impaired health-related quality of life (HRQoL) (SNOT-22 ≥ 40), and olfactory dysfunction (anosmia on smell testing) and and diagnosis of comorbid asthma—were consistently met across all cohorts, highlighting a comparable baseline clinical severity. Here, IGHE is linked to asthma.